612 related articles for article (PubMed ID: 15828836)
21. Steroid derivatives as pure antagonists of the androgen receptor.
Gauthier S; Martel C; Labrie F
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
[TBL] [Abstract][Full Text] [Related]
22. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
[TBL] [Abstract][Full Text] [Related]
23. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
[TBL] [Abstract][Full Text] [Related]
24. Identification of steroid derivatives that function as potent antiandrogens.
Miyamoto H; Marwah P; Marwah A; Yang Z; Chung CY; Altuwaijri S; Chang C; Lardy H
Int J Cancer; 2005 Dec; 117(5):866-72. PubMed ID: 15981214
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
Norris JD; Ellison SJ; Baker JG; Stagg DB; Wardell SE; Park S; Alley HM; Baldi RM; Yllanes A; Andreano KJ; Stice JP; Lawrence SA; Eisner JR; Price DK; Moore WR; Figg WD; McDonnell DP
J Clin Invest; 2017 Jun; 127(6):2326-2338. PubMed ID: 28463227
[TBL] [Abstract][Full Text] [Related]
26. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
Robitaille CN; Rivest P; Sanderson JT
Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
[TBL] [Abstract][Full Text] [Related]
27. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
[TBL] [Abstract][Full Text] [Related]
28. 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.
Miyamoto H; Marwah P; Marwah A; Lardy H; Chang C
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4440-4. PubMed ID: 12672951
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
Silva-Ortiz AV; Bratoeff E; Ramírez-Apan T; Heuze Y; Sánchez A; Soriano J; Cabeza M
Bioorg Med Chem; 2015 Dec; 23(24):7535-42. PubMed ID: 26631442
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice.
Nnane IP; Njar VC; Brodie AM
Cancer Chemother Pharmacol; 2003 Jun; 51(6):519-24. PubMed ID: 12715204
[TBL] [Abstract][Full Text] [Related]
31. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
[TBL] [Abstract][Full Text] [Related]
32. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
[TBL] [Abstract][Full Text] [Related]
33. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
34. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J
Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759
[TBL] [Abstract][Full Text] [Related]
35. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
Goto T; Ohta K; Fujii S; Ohta S; Endo Y
J Med Chem; 2010 Jul; 53(13):4917-26. PubMed ID: 20521823
[TBL] [Abstract][Full Text] [Related]
37. Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model.
Thankan RS; Thomas E; Purushottamachar P; Weber DJ; Njar VCO
Bioorg Chem; 2023 Oct; 139():106700. PubMed ID: 37392559
[TBL] [Abstract][Full Text] [Related]
38. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
39. Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A.
Liu W; Zhou J; Geng G; Shi Q; Sauriol F; Wu JH
J Med Chem; 2012 Jan; 55(2):971-5. PubMed ID: 22175694
[TBL] [Abstract][Full Text] [Related]
40. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
Latysheva AS; Zolottsev VA; Veselovsky AV; Scherbakov KA; Morozevich GE; Pokrovsky VS; Novikov RA; Timofeev VP; Tkachev YV; Misharin AY
Steroids; 2020 Jan; 153():108534. PubMed ID: 31678134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
